X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs WYETH LTD - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB WYETH LTD DR. REDDYS LAB/
WYETH LTD
 
P/E (TTM) x 31.2 27.7 112.4% View Chart
P/BV x 2.6 5.3 47.7% View Chart
Dividend Yield % 1.1 1.3 83.2%  

Financials

 DR. REDDYS LAB   WYETH LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
WYETH LTD
Mar-13
DR. REDDYS LAB/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs3,3971,044 325.2%   
Low Rs2,560818 313.0%   
Sales per share (Unadj.) Rs856.5298.6 286.9%  
Earnings per share (Unadj.) Rs78.057.2 136.2%  
Cash flow per share (Unadj.) Rs139.958.4 239.5%  
Dividends per share (Unadj.) Rs20.0017.00 117.6%  
Dividend yield (eoy) %0.71.8 36.8%  
Book value per share (Unadj.) Rs739.8249.5 296.6%  
Shares outstanding (eoy) m165.7422.72 729.5%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x3.53.1 111.5%   
Avg P/E ratio x38.216.3 234.8%  
P/CF ratio (eoy) x21.315.9 133.5%  
Price / Book Value ratio x4.03.7 107.8%  
Dividend payout %25.729.7 86.4%   
Avg Mkt Cap Rs m493,63221,157 2,333.2%   
No. of employees `00022.70.5 4,610.0%   
Total wages/salary Rs m31,068400 7,767.0%   
Avg. sales/employee Rs Th6,259.013,787.4 45.4%   
Avg. wages/employee Rs Th1,369.8813.0 168.5%   
Avg. net profit/employee Rs Th569.72,643.3 21.6%   
INCOME DATA
Net Sales Rs m141,9616,783 2,092.8%  
Other income Rs m1,715353 486.4%   
Total revenues Rs m143,6767,136 2,013.4%   
Gross profit Rs m24,7221,617 1,528.6%  
Depreciation Rs m10,26627 38,594.0%   
Interest Rs m6346 11,527.3%   
Profit before tax Rs m15,5371,938 801.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m2,965632 469.0%   
Profit after tax Rs m12,9211,301 993.5%  
Gross profit margin %17.423.8 73.0%  
Effective tax rate %19.132.6 58.5%   
Net profit margin %9.119.2 47.5%  
BALANCE SHEET DATA
Current assets Rs m96,8376,984 1,386.6%   
Current liabilities Rs m84,1992,056 4,095.5%   
Net working cap to sales %8.972.6 12.3%  
Current ratio x1.23.4 33.9%  
Inventory Days Days7399 73.9%  
Debtors Days Days9824 408.0%  
Net fixed assets Rs m102,552244 41,977.9%   
Share capital Rs m829227 364.9%   
"Free" reserves Rs m121,7925,441 2,238.5%   
Net worth Rs m122,6215,668 2,163.4%   
Long term debt Rs m5,44925 21,796.0%   
Total assets Rs m218,1657,901 2,761.2%  
Interest coverage x25.5353.3 7.2%   
Debt to equity ratio x00 1,007.5%  
Sales to assets ratio x0.70.9 75.8%   
Return on assets %6.216.5 37.6%  
Return on equity %10.522.9 45.9%  
Return on capital %12.934.0 37.9%  
Exports to sales %54.60.2 25,028.2%   
Imports to sales %9.436.3 25.7%   
Exports (fob) Rs m77,52015 523,783.8%   
Imports (cif) Rs m13,2742,465 538.4%   
Fx inflow Rs m81,67015 537,302.6%   
Fx outflow Rs m26,3552,677 984.4%   
Net fx Rs m55,315-2,662 -2,077.9%   
CASH FLOW
From Operations Rs m21,444923 2,322.8%  
From Investments Rs m-18,404317 -5,807.5%  
From Financial Activity Rs m-3,692-481 767.6%  
Net Cashflow Rs m-1,144759 -150.7%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 5.4 11.3 47.8%  
FIIs % 35.3 7.2 490.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 30.4 50.3%  
Shareholders   75,885 21,978 345.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade on a Negative Note; Sensex Down Over 160 Points(12:30 pm)

After opening the day marginally higher, share markets in India witnessed selling pressure and are presently trading on a negative note.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


May 21, 2018 03:35 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS